Financial Contrast: Cadrenal Therapeutics (CVKD) versus Its Peers

Cadrenal Therapeutics (NASDAQ:CVKD) is one of 955 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Cadrenal Therapeutics to related businesses based on the strength of its profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Risk and Volatility

Cadrenal Therapeutics has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics’ rivals have a beta of 0.80, meaning that their average stock price is 20% less volatile than the S&P 500.

Valuation and Earnings

This table compares Cadrenal Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	-$8.36 million	-0.62
Cadrenal Therapeutics Competitors	$1.66 billion	$154.05 million	-3.88

Cadrenal Therapeutics’ rivals have higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 58.1% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 14.4% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cadrenal Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-128.67%	-117.76%
Cadrenal Therapeutics Competitors	-2,643.56%	-227.01%	-28.96%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Cadrenal Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	0	0	2	0	3.00
Cadrenal Therapeutics Competitors	6095	17833	42985	885	2.57

Cadrenal Therapeutics presently has a consensus target price of $3.50, suggesting a potential upside of 714.33%. As a group, “Pharmaceutical preparations” companies have a potential upside of 85.78%. Given Cadrenal Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Cadrenal Therapeutics is more favorable than its rivals.

Summary

Cadrenal Therapeutics beats its rivals on 8 of the 13 factors compared.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.